AnGes MG Inc.
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 --
業務概覽 AnGes Inc is a biopharmaceutical company. The company's development projects include - HGF plasmid, NFkB decoy oligonucleotide, and Therapeutic vaccine.
公司地址 7-7-15, Saito-asagi, 4F, Saito Bio-Incubator, Ibaraki, Osaka, JPN, 567-0085
電話號碼 --
傳真號碼 --
公司網頁 http://www.anges.co.jp
員工數量 41
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Ei Yamada, M.D.,PhD Director, Chief Executive Officer and President -- 31/03/2023
 
董事會成員
董事會 職務 更新日期
Dr. Ei Yamada, M.D.,PhD Director, Chief Executive Officer and President 31/03/2023
Mr. Junichi Komamura Independent Director 31/03/2023
Mr. Norikazu Eiki Independent Director 31/03/2023
Mr. Makoto Hara Independent Director 31/03/2023
Ms. Kimiko Murofushi Independent Director 31/03/2023
Mr. Naoya Sato Director 31/03/2023
 
所屬ETF (更新日期: 07/03/2026 03:44)
代號 名稱 佔比% ▼ 持有日期
GWXState Street® SPDR® S&P® Intl Sm Cp ETF0.02%27/02/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%27/02/2026
DFICDimensional International Core Eq 2 ETF<0.000001%07/10/2025
DFSIDimensional International Sstby Cr 1 ETF<0.000001%07/10/2025
DXIVDimensional International Vector Eq ETF<0.000001%07/10/2025
HSCZiShares Currency Hdgd MSCI EAFE SmCp ETF<0.000001%27/02/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.